Three misconceptions about JCA
Navigating Europe's Joint Clinical Assessment (JCA) process requires understanding what's required—and what's not. Many sponsors hold misconceptions about Joint Scientific Consultations, the relationship between JCA reports and national reimbursement decisions, and how EMA approval influences JCA outcomes.
Watch this video for more on the realities of the JCA process and how to develop a winning evidence generation strategy.
Related Insights
CTB Video
JCA strategy: Predicting and prioritizing PICOs
Jan 22, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
Are unanchored matching-adjusted indirect comparisons a non-starter in EU Joint Clinical Assessments?
Jul 7, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
Blog
One year into EU JCA: Practical insights from the European Commission and Danish Medicines Council
Feb 18, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Webinar
Investor-ready strategy: Integrated evidence planning to maximize commercial opportunity
Sep 17, 2025
Playbook
JCA in the EU: A roadmap for sponsors
Aug 5, 2025
Blog
Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance
Jun 17, 2025
Blog
Using Managed Entry Agreements to address JCA-era uncertainties
May 13, 2025
Whitepaper
Employing Bayesian survival and cost-effectiveness modelling for more informed healthcare decision-making: Practical overview and current perspectives
Mar 28, 2025
Related Insights
CTB Video
JCA strategy: Predicting and prioritizing PICOs
Jan 22, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
Are unanchored matching-adjusted indirect comparisons a non-starter in EU Joint Clinical Assessments?
Jul 7, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
Blog
One year into EU JCA: Practical insights from the European Commission and Danish Medicines Council
Feb 18, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Webinar
Investor-ready strategy: Integrated evidence planning to maximize commercial opportunity
Sep 17, 2025
Playbook
JCA in the EU: A roadmap for sponsors
Aug 5, 2025
Blog
Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance
Jun 17, 2025
Blog
Using Managed Entry Agreements to address JCA-era uncertainties
May 13, 2025
Whitepaper
Employing Bayesian survival and cost-effectiveness modelling for more informed healthcare decision-making: Practical overview and current perspectives
Mar 28, 2025